Mode-of-action, efficacy, and safety of a homologous multi-epitope vaccine in a murine model for adjuvant treatment of renal cell carcinoma.

@article{Doehn2009ModeofactionEA,
  title={Mode-of-action, efficacy, and safety of a homologous multi-epitope vaccine in a murine model for adjuvant treatment of renal cell carcinoma.},
  author={Christian Doehn and Norbert Esser and H G Pauels and Stephan T. Kiessig and Matthias Stelljes and Armin Grossmann and Dieter Jocham and Joachim Drevs},
  journal={European urology},
  year={2009},
  volume={56 1},
  pages={123-31}
}
BACKGROUND AND OBJECTIVE In a phase-III trial it was recently shown that an adjuvant renal cell carcinoma (RCC) vaccine (Reniale) reduces the risk of tumour progression following nephrectomy. This clinical trial focused on efficacy and did not investigate end-points relating to mode-of-action of the vaccine. In a murine model we investigated mode-of-action, efficacy, and safety of a homologous RENCA cell-based vaccine. DESIGN, SETTING, AND PARTICIPANTS Six groups with 12 BALB/c mice per group… CONTINUE READING